Eto tyk slagam ne6to svarzano s nivata na THS. Ne znam mnogo angliiski, taka 4e 6te se naloji vseki sam da si go prevede.
Abstract. Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H (Aker University Hospital, Oslo; National Hospital, Oslo; Akershus Central Hospital, Nordbyhagen; and Ullevål University Hospital, Oslo, Norway). Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251: 400–406.
Objectives. Treatment of chronic hepatitis C with interferon-α (IFN-α) may induce thyroid disorders. We evaluated whether this risk is related to the dosage of IFN-α or the virological treatment response. Other possible risk factors as well as the evolution of the thyroid abnormalities were also studied.
Methods. In this prospective trial (n=254), thyroid-stimulating hormone (TSH), free thyroxin (fT4) and thyroid peroxidase autoantibodies were measured before, during and after treatment for hepatitis C virus (HCV). The patients were randomized to either induction therapy [IFN-α 6 million units (MIU) daily for 4 weeks and 3 MIU 3/7 days for 22 weeks] or conventional therapy [IFN-α 3 MIU 3/7 days for 26 weeks]. In addition, all patients received ribavirin (1000 or 1200 mg) daily. Sustained virological response was defined as loss of detectable HCV RNA at 6 months follow-up. Thyroid dysfunction was defined as TSH level below or above the normal range (0.2–4.5 MIU L1).
Results. Biochemical thyroid dysfunction developed in 30 (11.8%) of 254 patients. Hypothyroidism (TSH > 4.5 MIU L1) was seen in 20 and hyperthyroidism (TSH < 0.2 MIU L1) in 10 patients. Nine of the 30 patients developed symptomatic thyroid disease and HCV treatment was discontinued because of thyroid dysfunction in three of these patients. Thyroid dysfunction occurred in 15 (11.7%) of 128 patients who received high-dose IFN-α induction therapy as compared with 15 (11.9%) of 126 patients who received conventional IFN-α therapy (P=0.96). Amongst 231 patients who completed all 6 months of HCV treatment, a sustained virological response was obtained in 19 (66%) of 29 with thyroid dysfunction and 109 (54%) of 202 without (P=0.24). By multivariate analysis female gender and Asian origin were independent predictors of developing biochemical thyroid dysfunction (P < 0.01).
Conclusion. Thyroid dysfunction occurred in 11.8% of patients treated for chronic hepatitis C with IFN-α and ribavirin. Neither the IFN-α dosage nor the virological response to treatment were related to the incidence of thyroid dysfunction.